Show simple item record

dc.contributor.authorWorld Health Organization, Regional Office for South-East Asia
dc.coverage.spatialNew Delhien_US
dc.date.accessioned2016-05-14T05:36:29Z
dc.date.available2016-05-14T05:36:29Z
dc.date.issued2013
dc.identifier.govdocSEA-GLP-2013.1
dc.identifier.urihttps://apps.who.int/iris/handle/10665/206354
dc.description.abstractThe WHO Global Leprosy Programme organized a meeting on "Sentinel Surveillance for Drug Resistance in Leprosy" at Cotonou, Benin on 12-13 November 2012. Representatives from five national programmes, scientists from eight reference laboratories and experts from collaborating centers participated in the meeting. Data on registered relapse cases from five national programmes and information on laboratory findings from eight reference laboratories of the surveillance network were discussed in the meeting. The conclusions from the meeting emphasized the need for expansion of the surveillance network to improve continuous monitoring of relapse cases in all national programmes, with special focus on treatment completion and drug resistance. It was gratifying to note that rifampicin resistance was rare in all countries reporting data for 2011-2012 and the standard WHO-recommended MDT regimens remain the treatment of choice for leprosy.en_US
dc.language.isoenen_US
dc.publisherWHO Regional Office for South-East Asiaen_US
dc.subjectLEPROSYen_US
dc.titleSentinel surveillance for drug resistance in leprosy, 2012en_US
dc.title.alternativeReport of the WHO Global Programme Meeting Cotonou, Benin, 12-13 Nov 2012en_US
dc.typeMeeting reportsen_US


Files in this item

Thumbnail

This item appears in the following Collection(‎s)‎

Show simple item record